Caris Life Sciences, Inc.
Caris Life Sciences, Inc. (CAI) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cai · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Caris Life Sciences, Inc. (CAI) measures how much investors pay for each dollar of the company's trailing earnings. CAI's current PE ratio of 139.31x is calculated by dividing its stock price of $16.73 by its TTM earnings per share of $0.12. +400.8% elevated vs 5Y avg 27.8x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2005 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 15 fiscal years · Front-end computedMinQ1 · 25%17.7x
MedianQ3 · 75%113.3x
Max
At 139.31x, CAI's current P/E is higher than in 100% of its annual fiscal year readings over the past 15 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Caris Life Sciences, Inc.You CAI | $4.7B | 139.31x | +351.4% | $0.12 |
 Abivax S.A. ABVX | $6.8B | N/A | — | -$4.83 |
 Corcept Therapeutics Incorporated CORT | $8.1B | 36.27x | +17.5% | $0.96 |
 Cytokinetics, Incorporated CYTK | $8.7B | N/A | — | -$6.54 |
 Halozyme Therapeutics, Inc. HALO | $8.5B | 25.45x | -17.5% | $2.64 |
 Jazz Pharmaceuticals plc JAZZ | $14.8B | N/A | — | -$5.84 |
 Madrigal Pharmaceuticals, Inc. MDGL | $11.0B | N/A | — | -$12.85 |
Industry Average 2 peers with valid PE | — | 30.86x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.32 | — | |
2024-12-31 FY2024 | — | $-1.11 | — | |
2023-12-31 FY2023 | — | $-1.34 | — | |
2022-12-31 FY2022 | — | $-1.26 | — | |
2020-12-31 FY2020 | 18.12x | $1.55 | +11.4% | |
2019-12-31 FY2019 | 16.26x | $1.72 | +130.3% | |
2018-12-31 FY2018 | 7.06x | $3.97 | -5.6% | |
2017-12-31 FY2017 | 7.48x | $3.74 | -91.7% | |
2016-12-31 FY2016 | 90.20x | $0.31 | +316.2% | |
2015-12-31 FY2015 | 21.67x | $1.29 | +125.0% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Caris Life Sciences, Inc. (CAI) measures how much investors pay for each dollar of the company's trailing earnings. CAI's current PE ratio of 139.31x is calculated by dividing its stock price of $16.73 by its TTM earnings per share of $0.12.
Frequently asked questions
CAI pe ratio · 6 questionsCAI's current PE ratio is 139.31x as of 2026-06-08, based on a stock price of $16.73 and TTM EPS of $0.12. Data sourced from Financial Modeling Prep via CAI's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Caris Life Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08